Approximately 70% of patients with HR+/HER2− breast cancer who initially respond to CDK4/6 inhibitors develop resistance without acquiring new somatic mutations11, highlighting the role of nongenetic mechanisms. The gene discussed is CDK4; the disease is breast cancer.